OPM-201
Parkinson's Disease (focus on LRRK2 genetic variants)
Phase 1b/2FIH (SAD/MAD) completed Dec 2024. Program returned from Servier. Ready for Phase 1b/2.
Key Facts
Indication
Parkinson's Disease (focus on LRRK2 genetic variants)
Phase
Phase 1b/2
Status
FIH (SAD/MAD) completed Dec 2024. Program returned from Servier. Ready for Phase 1b/2.
About Oncodesign Precision Medicine
Oncodesign Precision Medicine is a publicly traded biotech focused on developing innovative therapeutic and diagnostic solutions for resistant cancers and neurodegenerative diseases. Its core strength lies in the Nanocyclix® platform, which generates highly selective macrocyclic kinase inhibitors, enabling a pipeline with first-in-class and best-in-class potential. The company has secured strategic validation and funding from The Michael J. Fox Foundation for its Parkinson's program and is advancing multiple clinical-stage assets while exploring radiotheranostic approaches through collaborative projects like COMETE.
View full company profile